Our team leverages this foundational knowledge along with insights gained over the last 20 years of drug development in the Alzheimer’s space to develop new approaches to address this complex disease.
Recent data suggests that timely intervention with anti-amyloid therapy results in clinical efficacy consistent with the slowing of disease progression. Such therapies, if approved, have the potential to fundamentally change how we treat Alzheimer’s disease. These first-generation therapies are likely to require further development to increase patient access and enhance the patient experience.
Prothena’s Alzheimer’s disease portfolio spans next generation antibody immunotherapy, small molecule and vaccine approaches, geared toward building upon first generation treatments to advance the treatment paradigm.
Prothena has initiated a Phase 1 study of PRX012, a potential best-in-class, next-generation anti-amyloid beta (Aβ) antibody under investigation for the treatment of Alzheimer’s disease. PRX012 has been granted Fast Track designation by the U.S. Food and Drug Administration.
A Phase 1 study of PRX005, a humanized monoclonal antibody under investigation for the treatment of Alzheimer’s disease in collaboration with Bristol Myers Squibb, has also initiated.